2.Alleviation of cancerous pain by external compress with Xiaozheng Zhitong Paste.
Yan-ju BAO ; Bao-jin HUA ; Wei HOU ; Hong-sheng LIN ; Xian-bin ZHANG ; Gui-xiang YANG
Chinese journal of integrative medicine 2010;16(4):309-314
OBJECTIVETo observe the clinical effectiveness of a topical application of Xiaozheng Zhitong: Paste (, XZP) in alleviating the cancerous pain of patients with middle/late stage cancer
METHODSBy: adopting a random number table, 124 patients enrolled were randomized into the treatment group (64 patients) and the control group (60 patients). In addition to the basic therapy [including the three-ladder (3L) analgesia] used in both groups, topical application of XZP was given to patients in the treatment group for pain alleviation. The analgesic efficacy was recorded in terms of pain intensity, analgesia initiating time and sustaining time, and the optimal analgesic effect revealing time. Meanwhile, the quality of life (QOL) and adverse reactions that occurred in patients were recorded as well.
RESULTSThe total effective rate in the treatment group was: 84.38% (54/64), and in the control group it was 88.33% (53/60), showing no significant difference between them (P>0.05), but the analgesia initiating time and the optimal analgesia effect revealing time in the treatment group were significantly shorter (both P<0.01). Moreover, XZP was better in improving patients' QOL, showing more significant improvements in the treatment group than those in the control group in aspects of mental condition, walking capacity, working capacity, social acceptability, sleep and joy of living (P<0.05 or P<0.01). Lower incidence of adverse reactions, such as nausea, vomiting, mouth dryness, dizziness, etc., especially constipation, was noted in the treatment group (P<0.05 or P<0.01).
CONCLUSIONApplying an external compress: of XZP showed a synergistic action with 3L analgesia for shortening the initiating time and the optimal effect revealing time, and could evidently enhance patients' QOL with fewer adverse reactions.
Aged ; Analgesics ; adverse effects ; therapeutic use ; Drugs, Chinese Herbal ; adverse effects ; therapeutic use ; Emollients ; adverse effects ; therapeutic use ; Female ; Humans ; Male ; Middle Aged ; Neoplasms ; complications ; drug therapy ; Pain ; complications ; drug therapy ; Phytotherapy ; Quality of Life ; Time Factors ; Treatment Outcome
3.Guidelines for the Management of Atopic Dermatitis in Singapore.
Yong Kwang TAY ; Yuin Chew CHAN ; Nisha Suyien CHANDRAN ; Madeline Sl HO ; Mark Ja KOH ; Yen Loo LIM ; Mark By TANG ; Thamotharampillai THIRUMOORTHY
Annals of the Academy of Medicine, Singapore 2016;45(10):439-450
INTRODUCTIONAtopic dermatitis is a common, chronic pruritic condition affecting both children and adults, which has a negative impact on the quality of life. These guidelines were developed by an expert workgroup appointed by the Dermatological Society of Singapore, to provide doctors with information to assist in the management of their patients with atopic dermatitis. The workgroup members are experienced dermatologists with interest and expertise in eczemas.
MATERIALS AND METHODSWorkgroup members arrived at a consensus on the topics to be included. Relevant studies from the literature were assessed for best evidence, supplemented by the collective experience of the workgroup.
RESULTSFor mild atopic dermatitis, emollients, mild potency topical steroids and topical calcineurin inhibitors are recommended. For moderate-to-severe atopic dermatitis, the use of emollients, moderate-to-potent topical steroids, topical calcineurin inhibitors, wet dressings, antimicrobials for secondary skin infection, phototherapy, and systemic therapy (e.g. prednisolone, cyclosporine, azathioprine or methotrexate) may be warranted. Patients with moderate-to-severe atopic dermatitis should be managed in conjunction with a dermatologist.
CONCLUSIONGood outcomes can be achieved with an individualised therapeutic approach combined with adequate patient and parental education.
Administration, Cutaneous ; Adrenal Cortex Hormones ; therapeutic use ; Anti-Bacterial Agents ; therapeutic use ; Azathioprine ; therapeutic use ; Calcineurin Inhibitors ; therapeutic use ; Coinfection ; complications ; drug therapy ; Cyclosporine ; therapeutic use ; Dermatitis, Atopic ; complications ; immunology ; therapy ; Dermatology ; Disease Management ; Emollients ; therapeutic use ; Food Hypersensitivity ; immunology ; Humans ; Immunosuppressive Agents ; therapeutic use ; Methotrexate ; therapeutic use ; Patient Education as Topic ; Phototherapy ; Practice Guidelines as Topic ; Referral and Consultation ; Severity of Illness Index ; Singapore
4.Clinical use of a ceramide-based moisturizer for treating dogs with atopic dermatitis.
Ji Young JUNG ; Eui Hwa NAM ; Seol Hee PARK ; Seung Hee HAN ; Cheol Yong HWANG
Journal of Veterinary Science 2013;14(2):199-205
In humans, skin barrier dysfunction is thought to be responsible for enhanced penetration of allergens. Similar to conditions seen in humans, canine atopic dermatitis (CAD) is characterized by derangement of corneocytes and disorganization of intercellular lipids in the stratum corenum (SC) with decreased ceramide levels. This study was designed to evaluate the effects of a moisturizer containing ceramide on dogs with CAD. Dogs (n = 20, 3~8 years old) with mild to moderate clinical signs were recruited and applied a moisturizer containing ceramide for 4 weeks. Transepidermal water loss (TEWL), skin hydration, pruritus index for canine atopic dermatitis (PICAD) scores, and canine atopic dermatitis extent and severity index (CADESI) scores of all dogs were evaluated. Skin samples from five dogs were also examined with transmission electron microscopy (TEM) using ruthenium tetroxide. TEWL, PICAD, and CADESI values decreased (p < 0.05) and skin hydration increased dramatically over time (p < 0.05). Electron micrographs showed that the skin barrier of all five dogs was partially restored (p < 0.05). In conclusion, these results demonstrated that moisturizer containing ceramide was effective for treating skin barrier dysfunction and CAD symptoms.
Animals
;
Ceramides/*therapeutic use
;
Cholesterol/*therapeutic use
;
Dermatitis, Atopic/complications/drug therapy/physiopathology/*veterinary
;
Dog Diseases/*drug therapy/etiology/physiopathology
;
Dogs
;
Emollients/*therapeutic use
;
Epidermis/drug effects/physiopathology/ultrastructure
;
Fatty Acids, Nonesterified/*therapeutic use
;
Female
;
Male
;
Microscopy, Electron, Transmission/veterinary
;
Pruritus/drug therapy/etiology/physiopathology/veterinary
;
Republic of Korea
;
Ruthenium Compounds/chemistry
;
Water Loss, Insensible/drug effects